On January 13, 2021, Numab Therapeutics AG (Wädenswil, Switzerland) entered into a global co-development and regional licensing agreement with Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan) for Numab's novel multispecific anti-inflammatory drug candidate NM26- 2198, which blocks three key pathways in the pathophysiology of atopic dermatitis. The alliance builds on a collaboration and option agreement established in 2017. Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world. The parties will jointly develop NM26-2198 with Kaken covering the majority of global development costs up to clinical proof-of-concept. Upon successful commercialization of products resulting from the alliance, Kaken will receive certain payments from Numab up to a cap that is calculated based on previous R&D payments made by Kaken to Numab.
VISCHER acted as counsel to Numab. The team was led by Stefan Kohler (IP/Life Sciences) and Christoph Niederer (Tax).
Categories: Intellectual Property